Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: CNS trials

This article was originally published in Scrip

Executive Summary

In the CNS therapeutic area, 303 industry-sponsored Phase II and Phase III trials were initiated between 1 October 2009 and 30 September 2010. Phase II and Phase III trial starts were equally split, with continuing high interest in pain. Nociceptive pain had more new Phase II starts (27) and total initiated trials (54) than any other indication. Neuropathic pain ranked next in terms of trial starts (32) and nearly half of these targeted pain caused by diabetic neuropathy. Combining trials for both nociceptive and neuropathic pain symptoms, pain relief represented nearly one-third of total trial starts, reflecting a continuing industry trend of yearly R&D expenditure in this competitive area. Depression and multiple sclerosis followed pain as areas of steady interest. In depression, 21 of 31 trials were Phase III starts, most aimed at drug registration. These included Lundbeck's LuAA21004 and AstraZeneca's TC-5214, with both companies planning to file new drug applications in 2012. Trials initiated in MS remained high despite the recent approval of the first oral medication, FTY720. Phase II schizophrenia trials targeted cognitive dysfunction, while Phase III trials aimed at new oral formulations for approved drugs. Alzheimer's disease trials were overwhelmingly Phase II (16 of 22 trials), reflecting the difficulty in demonstrating significant efficacy in large Phase III studies, as seen in the failure of both the histamine receptor antagonist Dimebon and the secretase gamma inhibitor LY450139 programmes. Parkinson's disease, with 17 of 20 trial starts in Phase III, showed robust pipeline advancement in this area.

You may also be interested in...



Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

COVID Vaccines: Is Expanded Access A Better Option Than Emergency Use Authorization?

Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.

Tom Abrams’ Steady Leadership Guided US FDA Through Dramatic Changes In Rx Promotion

From the rise of DTC to the shadow of Caronia, Abrams, the long-time head of the Office of Prescription Drug Promotion, monitored dramatic changes in the pharmaceutical marketplace and regulatory environment. He retired from FDA on 23 October after a tenure marked as much by careful research projects and copious guidances as it was by promotional and legal upheavals.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel